A Study of DS-3939a in Participants With Solid Tumors
← catalyst calendarNCT07739966 · readout in 1,442 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
400estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-01 | estimated | When the study began enrolling |
| Primary completion | 2030-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Locally Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
Interventions
- Drug: DS-3939a
- Drug: Pembrolizumab — also filed as MK-3475
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: DS-1103a
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants With Dose-limiting Toxicities (DLTs)
measured During first cycle (Cycle length=21 days)
Part 1: Number of Participants With TEAEs
measured Up to approximately 4 years
Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by Investigator
measured Up to approximately 4 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed